Known targets — ChEMBL curated mechanism
BTKCACNA1CCACNA1DCACNA1FCACNA1SCACNA2D1CACNA2D2DRD2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQHRH1HTR2AP2RY12
The experimentally established mechanism targets of Sebetralstat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 20/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sebetralstat SCHEMBL22495502 | 0.95 | KLKB1 (0.84) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL22495486 | 0.95 | KLKB1 (0.94) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL22495499 | 0.95 | KLKB1 (0.94) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL17785421 | 0.94 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL29619273 | 0.94 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL19668181 | 0.93 | KLKB1 (0.90) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL22495449 | 0.93 | KLKB1 (0.98) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL28770013 | 0.93 | KLKB1 (0.98) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Feniralstat SCHEMBL22491814 | 0.92 | KLKB1 (0.85) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL28769406 | 0.92 | KLKB1 (0.88) | KLKB1CYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4151630-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AS KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2023-03-22 | — | — | EP | claimed |
| US-20240199573-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF | DRI UK LP (KY) | 2024-06-20 | — | — | US | disclosed |
| US-11739068-B2 | Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-08-29 | — | — | US | disclosed |
| EP-4151630-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AS KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2023-03-22 | — | — | EP | disclosed |
| EP-3464265-B1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AS KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-07-13 | — | — | EP | disclosed |
| CN-109379891-B | Polymorphs of a compound as kallikrein inhibitor | 卡尔维斯塔制药有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220041571-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF | DRI UK LP (KY) | 2022-02-10 | — | — | US | disclosed |
| US-11230537-B2 | Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| US-20200317633-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1 -({4-[2-OXOPYRIDIN-1-YL)METHYL]PHENYL} METHYL)PYRAZOLE-4-CARBOXAMIDE AS IALLIKREIN INHIBITORS | DRI UK LP (KY) | 2020-10-08 | — | — | US | disclosed |
| EP-3464265-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1 -({4-[2-OXOPYRIDIN-1 -YL)METHYL]PHENYL} METHYL) PYRAZOLE -4-CARBOXAMIDE AS KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017208005-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1 -({4-[2-OXOPYRIDIN-1 -YL)METHYL]PHENYL} METHYL) PYRAZOLE -4-CARBOXAMIDE AS KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739068-B2 | Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof | CYP3A4, CYP4B1, TPMT | KLKB1 4305/4885CYP3A4 1/4885CYP2C8 25/4885 |
| US-20220041571-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF | CYP3A4, CYP4B1, TPMT | KLKB1 4305/4885CYP3A4 1/4885CYP2C8 25/4885 |
| US-20200317633-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1 -({4-[2-OXOPYRIDIN-1-YL)METHYL]PHENYL} METHYL)PYRAZOLE-4-CARBOXAMIDE AS IALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KLKB1 1/4885CYP3A4 179/4885CYP2C8 366/4885 |
| US-11230537-B2 | Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885CYP3A4 141/4885CYP2C8 348/4885 |
| US-20240199573-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF | CYP3A4, CYP4B1, TPMT | KLKB1 4305/4885CYP3A4 1/4885CYP2C8 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.